A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Sotio Biotech Inc.
National Cancer Institute (NCI)
Bayer
M.D. Anderson Cancer Center
AstraZeneca
Merck Sharp & Dohme LLC
Mayo Clinic
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
City of Hope Medical Center
Novartis
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
OncoNano Medicine, Inc.
Compass Therapeutics
Regeneron Pharmaceuticals
NeoTX Therapeutics Ltd.
Transgene
Bolt Biotherapeutics, Inc.
Strand Therapeutics Inc.
Institut Bergonié
Hadassah Medical Organization
Sichuan Baili Pharmaceutical Co., Ltd.
Institut Curie
Valo Therapeutics Oy
Memgen, Inc.
Incyte Corporation
Cancer Research UK
MacroGenics
Numab Therapeutics AG
NuCana plc
Medicenna Therapeutics, Inc.
Genentech, Inc.
Novartis
UNICANCER
M.D. Anderson Cancer Center
Maria Sklodowska-Curie National Research Institute of Oncology
Theratechnologies
Kymab Limited
University Health Network, Toronto
SOLTI Breast Cancer Research Group
Seagen Inc.
Stanford University
BioAtla, Inc.
Vincerx Pharma, Inc.
Simcha IL-18, Inc.